I previously highlighted about the potential on Twitter about NYR about a week or so ago and was stalking an entry. Unfortunately I didn't get in.
But another stock in the exact same situation was NSB and could do a similar thing.
It is a bio in the same neurological space that has been sold down from over 50c to under 4c. Things look like they will really pick up soon with FDA submission and phase 1 trials also to start soon.
$5m MC with $5.5m cash when the R&D rebate comes in.
At a zero or slightly negative EV the first piece of good news will see it run hard like NYR did today.
